Colorectal Cancer Alliance announces up to $775,000 in available research funding

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Colorectal Cancer Alliance announced up to $775,000 in available funding for research in young-onset colorectal cancer, rectal cancer, and colorectal cancer prevention. The Alliance will award up to five research grants for work that will advance its mission of ending colorectal cancer within our lifetime.

The grants will be awarded through the Chris4Life Research Program, which was established in 2010 to honor the late Christine Sapienza and all who are affected by colorectal cancer. The Alliance is committed to investing $10 million in critical research by 2021, including $3 million specifically to young-onset colorectal cancer research.

Additional funding for rectal cancer research may become available pending further financial support.

Proposals will be accepted now through October 1 online.

Grant recipients will be notified in December, with funding to commence in January 2019. More information about each grant:


Young-onset colorectal cancer research grants

Up to three 2-year grants in the amount of $125,000 each will be awarded to support research in young-onset colorectal cancer. The focus of research could be, but is not limited to, the following:

  • The risk factors and causes associated with the rise in young-onset colorectal cancer.

  • Prevention and early detection strategies.

  • Better mechanisms for increasing long-term survival rates.

  • The psychosocial impacts of young-onset colorectal cancer and the overall social influence on daily survivorship.


Rectal cancer research grant

One 2-year grant in the amount of $250,000 will be awarded to support research on rectal cancer research. The focus of research could be, but is not limited to, the following:

  • The risk factors and causes associated with the rise in rectal cancer in adults 55 and younger.

  • Prevention and early detection strategies.

  • Better mechanisms for increasing long-term survival rates.

  • The psychosocial impacts of rectal cancer and the overall social influence on daily survivorship.

  • The exploration and recommendations for improvements in the number of cases associated with Low Anterior Resection Syndrome.


Prevention research grant

One grant in the amount of $150,000 will be awarded over a two-year period to support the work of a researcher while working on mentored, colorectal cancer prevention research. The focus of research could be, but is not limited to, the following:

  • Improving colorectal cancer screening compliance.

  • Improving patient understanding of colonoscopy results, especially implications for diagnosis of advanced adenoma as it pertains to personal and family risk.

  • Preventing colorectal cancer and/or advanced adenoma recurrence.

The goal of the Colorectal Cancer Alliance’s research program is to provide funding for innovative projects expected to lead to future funding from other peer-reviewed sources.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login